Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Researchers develop new "nanojuice" to help doctors better identify human gut

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots but each suffers limitations. Help is on the way.

7 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

Research on intestinal microbiota overturns vision of human gut ecosystem

An international research team within the MetaHIT consortium coordinated by INRA and involving teams from CEA, CNRS and Université d'Evry, has developed a new method to analyse the global genome, or the metagenome of the intestinal microbiota.

7 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Alaska to be hit hard with hospital infection penalties

Elsewhere, medical marijuana's usefulness in treating pain is questioned after New York lawmakers legalized it.

27 Jun 2014

First Edition: June 27, 2014

Today's early morning highlights from the major news organizations, including reports on an HHS announcement detailing some of the marketplace enrollment plans for next fall.

27 Jun 2014

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Yoshimi Shibata, Ph.D., professor of biomedical science in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has received a $380,552 grant from the National Institute of Complementary and Alternative Medicine of the National Institutes of Health to further investigate how microparticles called "chitin" found in crab, shrimp and lobster shells have anti-inflammatory mechanisms that could lead to the development of novel preventive and therapeutic strategies for individuals who suffer from inflammatory bowel disease (IBD) and others diseases.

24 Jun 2014

New research reveals gene's role in type 1 diabetes

New research describes details of how a diabetes-related gene functions on a biological pathway that affects the release of insulin. The study authors say that finding drugs that act on that pathway may eventually lead to a new treatment for type 1 diabetes.

20 Jun 2014

La Jolla Institute researchers advance work toward vaccine for heart disease

Research toward the world's first vaccine for heart disease continues to advance at the La Jolla Institute for Allergy and Immunology, with researchers demonstrating significant arterial plaque reduction in concept testing in mice.

18 Jun 2014

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

18 Jun 2014

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.

11 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Decision Resources Group finds that, when asked to indicate the relative importance of product attributes when prescribing a new drug for Crohn's disease (CD), the highest percentages of surveyed gastroenterologists in the United States and Europe selected efficacy over safety and tolerability or delivery.

22 May 2014

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have.

21 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Ferring launches new interactive website Guts4life for people with IBD

Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn's disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD).

19 May 2014

Study shows technology improves transition into adulthood for adolescents with chronic disease

Adolescents with chronic diseases (ACD), such as cystic fibrosis, gastrointestinal disorders (including Crohn's disease) and Type 1 diabetes, often find the transition of managing their health care needs into adulthood to be challenging.

19 May 2014

Study finds increased risk of hospitalization for heart failure in IBD patients

Heart failure hospitalisation more than doubles during inflammatory bowel disease (IBD) flares, according to a study of more than 5 million Danish people. The research was presented today at the Heart Failure Congress 2014, held 17-20 May, in Athens, Greece.

19 May 2014

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Researchers develop new "nanojuice" to help doctors better identify human gut

Treating ulcerative colitis and Crohn’s disease

Research on intestinal microbiota overturns vision of human gut ecosystem

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Alaska to be hit hard with hospital infection penalties

First Edition: June 27, 2014

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

New research reveals gene's role in type 1 diabetes

La Jolla Institute researchers advance work toward vaccine for heart disease

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Cell Science Systems launches new blood test profile for GI disorders

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Ferring launches new interactive website Guts4life for people with IBD

Study shows technology improves transition into adulthood for adolescents with chronic disease

Study finds increased risk of hospitalization for heart failure in IBD patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in